Institutional support is crucial for stocks. IBD's RS Rating measures market leadership on a scale of 1 to 99, with over 80 indicating potential growth. Apogee Therapeutics' stock is not in a buy zone yet, with flat earnings and sales.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing